ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,778.10
1.01%
S&P ASX All Technology
3,094.00
0.51%
Brent Oil
83.665
-0.28%
US Dollar vs AUD
1.51071
0.01%
Bitcoin
65,429.56
-1.59%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Vigil Neuroscience Inc (VIGL)

  7. Vigil Neuroscience Inc (VIGL) News

VIGL

Vigil Neuroscience (VIGL)

Vigil Neuroscience Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VIGL
DateTimeSourceHeadlineSymbolCompany
08/06/202407:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
08/06/202407:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
07/06/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
30/05/202421:05GlobeNewswire Inc.Vigil Neuroscience to Present in Upcoming June Investor ConferencesNASDAQ:VIGLVigil Neuroscience Inc
08/05/202421:40GlobeNewswire Inc.Vigil Neuroscience to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:VIGLVigil Neuroscience Inc
08/05/202407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
08/05/202407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
08/05/202407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
08/05/202407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
08/05/202406:35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIGLVigil Neuroscience Inc
08/05/202406:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
08/05/202406:05GlobeNewswire Inc.Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
18/04/202406:05GlobeNewswire Inc.Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
26/03/202422:05GlobeNewswire Inc.Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
20/03/202422:05GlobeNewswire Inc.Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerNASDAQ:VIGLVigil Neuroscience Inc
13/03/202422:05GlobeNewswire Inc.Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
12/03/202422:05GlobeNewswire Inc.Vigil Neuroscience to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VIGLVigil Neuroscience Inc
07/03/202408:25GlobeNewswire Inc.Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024NASDAQ:VIGLVigil Neuroscience Inc
02/03/202410:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
02/03/202409:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
01/03/202408:05GlobeNewswire Inc.Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024NASDAQ:VIGLVigil Neuroscience Inc
15/02/202403:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VIGLVigil Neuroscience Inc
08/02/202408:05GlobeNewswire Inc.Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:VIGLVigil Neuroscience Inc
12/01/202402:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
04/01/202408:30GlobeNewswire Inc.Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 MilestonesNASDAQ:VIGLVigil Neuroscience Inc
23/11/202308:05GlobeNewswire Inc.Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx ConferenceNASDAQ:VIGLVigil Neuroscience Inc
17/11/202308:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
17/11/202308:05GlobeNewswire Inc.Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATENASDAQ:VIGLVigil Neuroscience Inc
07/11/202323:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIGLVigil Neuroscience Inc
07/11/202323:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
 Showing the most relevant articles for your search:NASDAQ:VIGL

Your Recent History

LSE
66OC
Investec Bnk 23
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved